Tarlatamab's role in SCLC
Prof Jacob Sands speaks to ecancer about the primary analysis of the phase III DeLLphi-305 trial, which evaluated tarlatamab plus durvalumab versus durvalumab alone as first-line maintenance therapy in patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease had not progressed following initial treatment with durvalumab, platinum-based chemotherapy and etoposide.
Among 563 patients, adding tarlatamab to durvalumab significantly improved overall survival, with median overall survival increasing from 12.7 to 21.1 months.
Prof Sands says the combination also significantly improved progression-free survival, extending median progression-free survival from 1.9 to 7.4 months, and increased the objective response rate from 4.1% to 26.4%.
Grade 3 or higher treatment-emergent adverse events occurred in 46.8% of patients receiving the combination and 40.6% receiving durvalumab alone.
Cytokine release syndrome occurred in 49.6% of patients treated with tarlatamab plus durvalumab, while immune effector cell-associated neurotoxicity syndrome occurred in 1.1%; these events were primarily low grade, with no fatal events reported.
Dr Sands speculates that these findings could establish tarlatamab plus durvalumab as a new standard of care for first-line maintenance treatment of ES-SCLC.
Tarlatamab's role in SCLC
Izalontamab brenitecan shows promising activity in previously treated EGFR mutated NSCLC
Cemiplimab shows strong survival benefit in KRAS G12C positive advanced NSCLC
Amivantamab plus chemotherapy extends overall survival in EGFR exon 20 insertion NSCLC
Extended interval tarlatamab dosing shows consistent clinical activity in previously treated SCLC
JS207 plus chemotherapy enables surgery and deep pathological responses in unresectable NSCLC
Lorlatinib delivers 7-year progression-free survival and durable brain control in ALK+ NSCLC
Is radiotherapy a back up plan after neoadjuvant chemo-immunotherapy in perioperative lung cancer management?
Cemiplimab shows durable 6-year survival benefit in PD-L1 high advanced NSCLC